Zydus Lifesciences launches Bemdac to treat uncontrolled LDL-c

13 May 2022 Evaluate

Zydus Lifesciences has launched Bemdac (Bempedoic acid), a new class of drug for the first time in India. The oral drug ushers in a new line of treatment for patients suffering from uncontrolled levels of LDL-Cholesterol (LDL-c) despite life-style modifications and the use of maximum tolerated dose of statins, which form the cornerstone of dyslipidemia management. Bemdac is an important addition to Zydus’ portfolio of medicines for managing dyslipidemia and cholesterol.

LDL-c is often referred to as bad cholesterol since it gets deposited in the walls of the blood vessels, increasing the chances of health problems like heart attack or stroke. Uncontrolled LDL-c is a major risk factor for developing cardiovascular diseases.

Zydus Lifesciences is an India-based pharmaceutical company. The company's subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.

Zydus Lifesciences Share Price

888.00 -5.45 (-0.61%)
28-Jan-2026 10:47 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1616.75
Dr. Reddys Lab 1226.10
Cipla 1319.25
Zydus Lifesciences 888.00
Lupin 2125.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×